{"id":"6f18ca3e-1494-5751-8e8f-088d5b734ec7","stable_key":"1ff3a29f-ef80-5bff-9300-30b98c60b90d:strontium-soti-fractures","predicate":"reduces","statement":"In 1,649 postmenopausal women with osteoporosis and a prior vertebral fracture, 2 g/day ranelate reduced new vertebral-fracture risk over three years: relative risk 0.59, 95% CI 0.48–0.73.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"791aed85-3981-5a44-9edc-6a0101c1eade","mechanism_event_label":"A clinical trial measured fewer fractures, separately from density scans.","subject":{"id":"a319eca8-b0ed-5a8c-8659-e7f106bed73a","slug":"strontium-ranelate","display_name":"Strontium ranelate","entity_type_key":"chemical_species"},"object":{"id":"db282148-7905-53f7-8a5e-50c075350662","slug":"human-soti-vertebral-fractures","display_name":"New vertebral fractures in the SOTI trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"791aed85-3981-5a44-9edc-6a0101c1eade","stable_key":"1ff3a29f-ef80-5bff-9300-30b98c60b90d:strontium-soti-fractures-event","event_type":"observed_relationship","label":"A clinical trial measured fewer fractures, separately from density scans.","description":"In 1,649 postmenopausal women with osteoporosis and a prior vertebral fracture, 2 g/day ranelate reduced new vertebral-fracture risk over three years: relative risk 0.59, 95% CI 0.48–0.73.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"a319eca8-b0ed-5a8c-8659-e7f106bed73a","slug":"strontium-ranelate","display_name":"Strontium ranelate","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"db282148-7905-53f7-8a5e-50c075350662","slug":"human-soti-vertebral-fractures","display_name":"New vertebral fractures in the SOTI trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"2ca2864b-1ef0-54e4-8397-1dbe7207a0d2","slug":"strontium","display_name":"Strontium","entity_type_key":"nutrient_element"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"e359bc15-e675-5d83-b0fe-1d70814e130b","slug":"calcium-ion","display_name":"Calcium ion","entity_type_key":"ion"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"b162e431-b442-5400-9335-ec91f7875a4e","slug":"cholecalciferol","display_name":"Cholecalciferol","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized placebo-controlled SOTI trial; both groups received calcium and vitamin D.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Specific drug, population and co-treatment; no equivalent efficacy established for dietary strontium or strontium citrate. Trial mechanisms are not identified by the fracture endpoint.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Strontium collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"strontium","display_name":"Strontium","entity_type_key":"nutrient_element"}},{"dimension":"plain_language","value_text":"A clinical trial measured fewer fractures, separately from density scans.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. · 2004 · https://pubmed.ncbi.nlm.nih.gov/14749454/ · DOI 10.1056/NEJMoa022436","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"29c0628d-d78b-5509-be46-e891cd788819","evidence_kind":"source_excerpt","locator":"Lines 422-428","start_line":422,"end_line":428,"excerpt":"## strontium-soti-fractures\nA clinical trial measured fewer fractures, separately from density scans.\nIn 1,649 postmenopausal women with osteoporosis and a prior vertebral fracture, 2 g/day ranelate reduced new vertebral-fracture risk over three years: relative risk 0.59, 95% CI 0.48–0.73.\nModel: Randomized placebo-controlled SOTI trial; both groups received calcium and vitamin D.\nLimitations: Specific drug, population and co-treatment; no equivalent efficacy established for dietary strontium or strontium citrate. Trial mechanisms are not identified by the fracture endpoint.\nEvidence access: Primary abstract\nThe effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. · 2004 · https://pubmed.ncbi.nlm.nih.gov/14749454/ · DOI 10.1056/NEJMoa022436","model_system":"Randomized placebo-controlled SOTI trial; both groups received calcium and vitamin D.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"43ef0fe7-eb6c-5346-8381-f7694733b4dc","stable_key":"import-1ff3a29f-ef80-5bff-9300-30b98c60b90d","title":"Strontium: calcium interactions, cellular mechanisms and mineralization (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"51221949263cdf8a22a79c32e3989599de1a37dc215700e0a076f436b40a1005","revision_id":"84f6df49-c456-5ad2-8214-cc69d5dc7722","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}